With warmer weather, pet owners should take precautions against ticks
A dog getting exercise outside in Edmonton on May 25, 2025.
It's that time of year again in Edmonton: With warmer weather comes more time outside for pets and their owners.
It's also time for dog owners to take precautions to protect their canines from ticks.
Areas with long grass and trees are places in which one can expect ticks to be active.
Local veterinarian Vicki Janes says using regular tick prevention medication can help and adds owners should also be on the lookout for fleas and lice.
'There's also lots of natural dog bug repellents that are out there and spray foam that you can use if you're going camping or going to the lake,' Janes, of the Heartland Forest Veterinary Hospital, told CTV News Edmonton.
With files from CTV News Edmonton's Miriam Valdes-Carletti
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
an hour ago
- CBC
Take tick precautions, but Lyme disease rates remain quite low on Prince Edward Island
More and more ticks have been catching a ride into the province of P.E.I. over the last few years. Ticks have been known to attach themselves to human skin, as well as hop onto furry pets, but medical experts say it's not causing a big jump in Lyme disease rates so far. CBC's Tony Davis reports.
CBC
an hour ago
- CBC
New patient targets for family doctors could hurt P.E.I.'s reputation, says national college
The College of Family Physicians of Canada is raising concerns over new targets for family doctors on P.E.I. and calling on all parties to work together to find a solution. "I'm feeling pretty sad. There seems to have been a significant breakdown in trust and in the relationship, and that's really hard, when people stop being able to trust one another," college president Dr. Carrie Bernard told CBC News: Compass host Louise Martin. Last week, the Medical Society of Prince Edward Island announced plans for legal action against Health P.E.I., citing what it says is a breach of its agreement with the province. The society said the new targets for how many patients each doctor needs to accept are not what it agreed to when it signed a new physician services agreement with the province last year. Bernard said that agreement, which made P.E.I. the first province to officially recognize family medicine as a specialty, a move that includes higher pay, was celebrated across the country. But she said the recent policy development undermines that progress and can make physicians feel not valued and respected by the system in which they play a foundational role. Health P.E.I.'s new operational guide includes key performance indicators, or KPIs, that include a requirement that each family doctor will see 24 patients a day, based on an average appointment being 15 minutes long. It also says each full-time family doctor should have a minimum of 1,600 patients on the books, or panel size, which Bernard calls an "arbitrary number." Penalties can be imposed if the minimum isn't met. Impact on recruitment and retention On Monday, P.E.I. Health Minister Mark McLane told CBC News that the targets are intended to help the government collect information and evaluate how the new physician services agreement is working. He also pointed out that Health P.E.I. was giving doctors and their association six weeks to provide feedback on the new guidelines, and said there will be no punitive measures during the first year of the agreement. P.E.I. health minister 'confident' province, family doctors can reach compromise on workload targets 4 days ago Duration 7:17 Health Minister Mark McLane responded for the first time to the legal battle brewing between the province's medical society and the P.E.I. government over new targets for how many patients family physicians see per day. McLane tells CBC News: Compass host Louise Martin that the guidelines are still in draft form, and says he wants to work with doctors to resolve their pending legal challenge. Bernard agreed that accountability matters. "I don't think any family physician thinks they should not be accountable. We expect the accountabilities, however, to be informed by the professionals who are actually providing the care," she said. The good news story 100 per cent was well shared across the country with great excitement, and right now there is a significant pause in that good news and a significant second look across the country about what's going to happen in P.E.I. — Dr. Carrie Bernard "This just sort of came out of nowhere, without consultation and discussion and collaboration and negotiation." She added that setting a blanket number for patient panels is too simplistic and doesn't reflect the reality of family practice. Bernard warned that just as the news of last year's agreement was celebrated across the country, this policy shift could have consequences on physician recruitment and retention. "Family doctors talk, and they talk to each other, not just to recruiters," she said. "So the good news story 100 per cent was well shared across the country with great excitement, and right now there is a significant pause in that good news and a significant second look across the country about what's going to happen in P.E.I." New target 'out of keeping' with national average Bernard said the 1,600 figure is "out of keeping" with the national average of about 1,200 patients per family physician. "The issue of numbers is that if a doctor has too many patients for the number of hours they have available to see their patients, you might have a family doctor in name, but you may not be able to actually see your family doctor," she said. She added that even the 1,200 average can vary greatly depending on the complexity of patients. Society representing P.E.I. doctors is suing Health P.E.I. over new targets for family physicians 7 days ago Duration 2:40 Health P.E.I. is planning to change how family physicians are expected to work in the province. The Medical Society of P.E.I. says that was not part of negotiations that led up to a new Physician Services Agreement, so it has initiated legal action, saying some doctors will leave the province over this. CBC's Stacey Janzer reports. For instance, doctors who serve many patients with chronic illnesses, as well as newcomers or refugee families who require translation, may need to spend more time per visit, which means they can handle fewer patients overall. The same is true for physicians with added responsibilities, such as teaching or taking on leadership roles in the community or hospital system, she said. "In smaller places like Prince Edward Island, where we're asking many family doctors to take on leadership roles — same thing," she said. "If you have to take on a leadership role, either in your family health team or at the hospital, that limits the number of patients you can see."
National Post
an hour ago
- National Post
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
Article content Article content – Patient dosing is underway in the Phase 3 CYB003 PARADIGM program in Major Depressive Disorder ('MDD') with expected combined enrollment of approximately 550 participants across three studies (APPROACH™, EMBRACE™, and EXTEND) – Article content Article content – Partnerships with Osmind and Thermo Fisher Scientific strengthen the Company's commercialization and manufacturing capabilities – Article content – Positive regulatory signals from U.S. Agencies amid expanding media coverage could expedite regulatory pathways across Cybin's clinical-stage pipeline – Article content TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update. Article content 'It is especially gratifying that at a time when we are advancing our clinical pipeline programs, with our lead program CYB003 in Phase 3 development, the path toward approval and eventual commercialization of psychedelic therapeutics is gaining clarity,' said Doug Drysdale, Chief Executive Officer of Cybin. 'With our expanded intellectual property portfolio, and a number of key partnerships in place, we believe our rigorous research and novel clinical approach can lead to a transformation in how mental health disorders are treated. Now is the time to address the mental health crisis, and we are encouraged by recent sentiment in favor of expediting the regulatory review process for product candidates in development.' Article content Continued to expand its strategic clinical site partnership ('SPA') program in support of the Phase 3 PARADIGM program. The SPA program is designed to facilitate collaboration among sites, enhance efficiency in trial operations, and improve overall site performance. Partnered with Thermo Fisher Scientific, a world-class manufacturing partner, to provide U.S.-based manufacturing for the CYB003 program. Cybin broadened its existing strong relationship with Thermo Fisher Scientific to include the development of both the drug substance and drug product capsules for CYB003. Partnered with Osmind, a leading service provider to psychiatry practices in the U.S., with the objective of accelerating commercial preparation for clinical-stage pipeline. Osmind advances psychiatry through technology and services to bring innovative mental health treatments to patients in need. Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support commercial preparation for its clinical-stage pipeline. Continued to expand intellectual property portfolio with two additional U.S. patents supporting lead programs CYB003 and CYB004, bringing the total to over 90 granted patents and over 230 pending applications. The recently issued patents are as follows: U.S. patent 12,291,499 includes pharmaceutical compositions and oral dosage forms within the CYB003 program with expected exclusivity until 2041. U.S. patent 12,318,477 is expected to provide exclusivity until 2040 and includes claims to novel formulations of DMT and deuterated isotopologues for intramuscular ('IM') injection, including CYB004. Article content Positive Regulatory Signals and Evolving Acceptance of Potential Therapeutic Value of Psychedelics Article content Recent statements and hiring decisions by senior U.S. Health and Human Services ('HHS') and FDA officials, in addition to ongoing signs of bipartisan congressional support, suggest an improved forward regulatory environment for psychedelic medicine and therapies, including the potential for accelerated approval pathways. Article content The Company believes that these developments, together with increased political recognition and public understanding of the science underpinning these programs, have the potential to expedite regulatory pathways and reduce overall risk across its clinical portfolio. Highlights include: Article content In a recent interview, FDA Commissioner Dr. Marty Makary stated that psychedelic-drug review is a 'top priority' and promised an 'expeditious and rapid review' of clinical data. 1 Article content Drug-policy lawyer, Matthew Zorn, has joined HHS as Deputy General Counsel to work on psychedelics policy. He previously challenged the government on matters such as allowing research on cannabis for veterans with PTSD, preventing tryptamines from being scheduled, and fighting for patient access to psilocybin under Right to Try laws. 2 Article content Navy-SEAL-turned-Congressman Morgan Luttrell recently urged the GOP to 'embrace' compounds such as psilocybin, MDMA and ibogaine to help veterans with PTSD. 3 Article content President Trump's new pick for surgeon general, Dr. Casey Means, wrote in a recent book that people should consider guided-psychedelic therapy. 4 Article content On June 19, 2025, Doug Drysdale will speak in a panel discussion focused on the regulatory landscape and next steps for potential commercialization, at the Psychedelic Science 2025 Conference taking place June 16-20, 2025, in Denver, Colorado. The panel details are as follows: Article content Panel Title: Article content Date and Time: Article content About Cybin Article content Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Article content With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Article content Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Sources Article content NewsNation, 'FDA Commissioner Says Research on Psychedelic Treatment 'Top Priority',' interview with FDA Commissioner Dr. Marty Makary, video posted May 16, 2025, (accessed June 9, 2025). Politico, 'A Psychedelics Hire at HHS,' newsletter article, published May 28 2025, (accessed June 9 2025). The Wall Street Journal, 'Lawmaker 'Reborn' Through Psychedelic Therapy Wants the GOP to Embrace It,' news article, published May 17 2025, (accessed June 9 2025). The Associated Press, 'Trump Surgeon General Pick Praised Unproven Psychedelic Therapy, Said Mushrooms Helped Her Find Love,' news article, published May 14 2025, (accessed June 9 2025). Fox News. 'Trump Administration Exploring Potential Benefits of Psychedelic Treatments.' America's Newsroom, correspondent Alexandria Hoff, broadcast June 5 2025. Video clip, 1:58. Article content Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to enroll participants and add additional clinical sites for the PARADIGM program; regulatory statements that suggest an expedited regulatory pathway for Cybin programs; the anticipated approval and commercialization of CYB003 and CYB004; the ability to accelerate commercial preparation of clinical-stage programs through the Company's partnership with Osmind; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. Article content These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Article content Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Article content Article content Article content Article content Article content Contacts Article content Investor & Media: Article content Article content Gabriel Fahel Article content Article content Chief Legal Officer Article content Article content Cybin Inc. Article content Article content Article content Article content
